+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Liver Fluke Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997590
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Merck & Co., Inc
  • Novartis AG
  • Romark Laboratories, L.C.
  • Zoetis Inc
  • MORE
The Liver Fluke Treatment Market is expected to register a CAGR of 4.2% during the forecast period. Liver flukes are parasites that can cause disease called fascioliasis in humans, cattle, and sheep. The liver fluke infection is caused by worms such as Fasciola hepatica and Fasciola gigantica. Infections in humans usually occur after eating contaminated raw or undercooked freshwater fish or watercress. Liver fluke infected individuals mostly don’t show any symptoms, sometimes symptoms arise related to the biliary system. In rare cases, long-term complications can also develop. Some of the symptoms of liver fluke infection are abdominal pain, malaise, diarrhea, nausea and vomiting, fever and decreased appetite and weight loss.

According to the Centers for Disease Control and Prevention (CDC), fascioliasis occurs in many areas of the world, which is a common liver fluke of sheep and cattle. Moreover, fascioliasis is more common and widespread in animals than in people. Even so, the number of infected people is thought to exceed two million worldwide. In addition, as per the study published in The American Journal of Tropical Medicine and Hygiene, estimates prevalence of 2.6 million infected and 91 million at risk of developing infection worldwide.

Increasing cases of liver fluke infection in humans and animals, and growing awareness on liver fluke infections among population are the key driving factors in liver fluke treatment market.

Key Market Trends

Triclabendazole Segment is Expected to Hold a Major Market Share in the Liver Fluke Treatment Market
  • Triclabendazole is a benzimidazole compound used routinely in veterinary practice for the treatment of fascioliasis. In the year 1997, after the success of clinical trials using triclabendazole for the treatment of fascioliasis, the World Health Organization (WHO), recommended that the drug be placed on the Essential Drugs List.
  • According to the World Health Organization (WHO), estimates worldwide at least 2.4 million people are infected with fascioliasis in more than 70 countries, with several million at risk. In addition, infection is present in domestic animals in almost all countries where cattle and sheet are reared.
  • Triclabendazole segment holds a significant market share in the liver fluke treatment market and is anticipated to show similar trend over the forecast period.
  • Moreover, triclabendazole is highly effective compare to other drugs and it is considered as first-line therapy against liver fluke infections by Center for Disease Control (CDC) and the World Health Organization (WHO).
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global liver fluke treatment market due to increasing prevalence of Fasciola hepatica infections in cattle and sheep in this region. As per the study published in The American Journal of Tropical Medicine and Hygiene, estimates veterinary disease is prevalent in multiple areas in the United States and may be expanding. Moreover, high prevalence of Fasciola hepatica infections in cattle in California and in some areas 90% of adult cattle are infected with Fasciola hepatica. Furthermore, increase in research and development for liver fluke treatment is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Liver Fluke Treatment Market is fragmented competitive and consists of a several major players. some of the leading market players include Novartis AG, GlaxoSmithKline Plc, Bayer AG (Bayer Animal Health), Endo International Plc (Par Pharmaceutical), Romark Laboratories, L.C., Zoetis Inc, Merck & Co., Inc, Lupin Pharmaceuticals, Inc and Schering-Plough Corporation among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Merck & Co., Inc
  • Novartis AG
  • Romark Laboratories, L.C.
  • Zoetis Inc
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Fascioliasis Infection in Humans and Cattle
4.2.2 Raising Awareness on Liver Fluke, Fascioliasis Infection Among the People by Government Organizations
4.2.3 Increasing Research and Development for Liver Fluke Treatment
4.3 Market Restraints
4.3.1 Requirement of Long Treatment Cycles for Liver Fluke Infection
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Albendazole
5.1.2 Praziquantel
5.1.3 Triclabendazole
5.1.4 Nitazoxanide
5.1.5 Other Drugs
5.2 By Application
5.2.1 Human
5.2.2 Cattle
5.2.3 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 GlaxoSmithKline Plc
6.1.3 Bayer AG (Bayer Animal Health)
6.1.4 Endo International Plc (Par Pharmaceutical)
6.1.5 Romark Laboratories, L.C.
6.1.6 Zoetis Inc
6.1.7 Merck & Co., Inc
6.1.8 Lupin Pharmaceuticals, Inc
6.1.9 Schering-Plough Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG (Bayer Animal Health)
  • Endo International Plc (Par Pharmaceutical)
  • Romark Laboratories, L.C.
  • Zoetis Inc
  • Merck & Co., Inc
  • Lupin Pharmaceuticals, Inc
  • Schering-Plough Corporation
Note: Product cover images may vary from those shown
Adroll
adroll